Clinical Trial

Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS

Study acronym: PCOS HOMA IR
Completed
View on ClinicalTrials.gov →
Summary
Women with PCOS with HOMA-IR \>2 fulfilling inclusion and exclusion criteria are randomly allocated into two groups: group A: pioglitazone 30 mg once daily and group B: Metformin 500 thrice daily for 3 months.Each group contains 30 participants. Outcome variables are measured after 3 months.
Trial Details
NCT Number NCT07472179
Lead Sponsor Mst.Sumyara Khatun
Collaborators: Bangladesh Medical University
Conditions PCOS(Insulin Resistant)
Enrollment 60 participants
Start Date 2024-08-12
Primary Completion 2025-12-12 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-16